Literature DB >> 20484131

Increases in waist circumference and weight as predictors of type 2 diabetes in individuals with impaired fasting glucose: influence of baseline BMI: data from the DESIR study.

Alain Gautier1, Ronan Roussel, Pierre H Ducluzeau, Céline Lange, Sylviane Vol, Beverley Balkau, Fabrice Bonnet.   

Abstract

OBJECTIVE: To evaluate in impaired fasting glucose (IFG) the relative importance of increases in waist circumference and weight on progression to type 2 diabetes. RESEARCH DESIGN AND METHODS: The 9-year incidence of diabetes was studied in 979 men and women with baseline IFG, from the Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort.
RESULTS: Increases in both waist circumference and weight were significantly associated with diabetes incidence. Standardized odds ratios (95% CI) were 1.79 (1.45-2.21) and 1.86 (1.51-2.30), respectively, after controlling for baseline risk factors. The impact of waist circumference increase was greater for BMI <25 kg/m(2) (2.40 [1.63-3.52]) than for BMI >or=25 kg/m(2) (1.66 [1.28-2.16]) and persisted after adjusting for concurrent changes in either insulinemia or the homeostasis model assessment of insulin resistance index. Weight change had a similar impact in both BMI groups.
CONCLUSIONS: In individuals with IFG, it is important to monitor and prevent increases in waist circumference, in particular for those with BMI <25 kg/m(2).

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20484131      PMCID: PMC2909076          DOI: 10.2337/dc10-0368

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


Individuals with impaired fasting glucose (IFG) are at high risk for type 2 diabetes (1,2). Although visceral adiposity and waist circumference are strong risk factors for type 2 diabetes (3), the consequence of an increase in waist circumference among individuals with IFG at baseline has not been fully investigated, in particular in those who are not overweight or obese at baseline (4,5). This report investigates the relative importance of increases in waist circumference and weight on progression to diabetes in individuals with baseline IFG, according to baseline BMI strata.

RESEARCH DESIGN AND METHODS

We studied men and women aged 30–64 years, who participated in the Data from an Epidemiological Study on the Insulin Resistance Syndrome (DESIR) cohort and who had IFG at baseline (fasting plasma glucose 5.6–6.9 mmol/l). DESIR is a 9-year follow-up study that aimed to clarify the development of the insulin resistance syndrome and type 2 diabetes (6). All participants signed an informed consent, and the protocol was approved by an ethics committee. Incident cases of diabetes had fasting plasma glucose ≥7.0 mmol/l or treated diabetes at one of the three yearly follow-up examinations. The average variation per year in waist circumference and weight was defined as the difference between the visit when diabetes was screened and the baseline visit divided by the number of years of follow-up. A total of 674 men and 305 women were studied. All analyses used R version 2.10.0 (Free Software Foundation, Boston, MA), and a two-sided P < 0.05 was considered statistically significant. Homeostasis model assessment of insulin resistance (HOMA2-IR) was computed using software downloaded at http://www.dtu.ox.ac.uk. Insulin, glucose, and HOMA2-IR values were log transformed before analysis. We used logistic models for incident diabetes to evaluate standardized odds ratios with Wald 95% CIs, conditioned on baseline BMI < and ≥25 kg/m2, adjusted for sex, family history of diabetes, baseline age, current smoking, physical activity, fasting glucose, and hypertension (systolic/diastolic blood pressures ≥140/ 90 mmHg or treated for hypertension). We tested for interactions between baseline BMI categories with increases in waist circumference and weight on incident diabetes.

RESULTS

There were 142 cases of incident diabetes after 9 years of follow-up. Individuals who became diabetic had a greater increase over follow-up in both waist circumference and weight than those who did not progress (online appendix Table 1, available at http://care.diabetesjournals.org/cgi/content/full/dc10-0368/DC1). Changes in waist circumference and weight were significantly associated with incident type 2 diabetes in multivariate analysis, in both BMI categories (Table 1). The significant impact of change in either waist circumference or weight did not vary by age at baseline (aged < or >50 years). There was an interaction between BMI category and the effect of waist increase for progression to diabetes, with a larger impact in participants with BMI <25 kg/m2 than in those with BMI ≥25 kg/m2 (P for interaction = 0.049).
Table 1

Odds ratios (95% CI) for 9-year incident diabetes, per 1 SD change in waist circumference and weight in IFG: the DESIR study

All IFG participants
BMI <25 kg/m2
BMI ≥25 kg/m2
n = 979
n = 433
n = 546
Odds ratio (95% CI) P Odds ratio (95% CI)* P Odds ratio (95% CI) P
Univariate
    Change in waist circumference1.69 (1.41–2.03)<0.00012.48 (1.73–3.55)<0.00011.48 (1.20–1.84)0.0003
    Change in weight1.83 (1.53–2.19)<0.00011.86 (1.35–2.55)<0.00011.85 (1.48–2.32)<0.0001
Model 1
    Change in waist circumference1.79 (1.45–2.21)<0.00012.40 (1.63–3.52)<0.00011.66 (1.28–2.16)0.0002
    Change in weight1.86 (1.51–2.30)<0.00011.92 (1.32–2.79)0.00061.96 (1.50–2.55)<0.0001
Model 2
    Change in waist circumference1.65 (1.30–2.09)<0.00011.82 (1.21–2.75)0.0041.66 (1.22–2.24)0.001
    Change in weight1.67 (1.30–2.15)<0.00011.20 (0.77–1.88)0.41.97 (1.44–2.69)<0.0001
Model 3
    Change in waist circumference1.52 (1.18–1.96)0.0011.82 (1.18–2.80)0.0071.49 (1.08–2.06)0.01
    Change in weight1.48 (1.13–1.95)0.0051.04 (0.64–1.70)0.91.79 (1.29–2.50)0.0006

Model 1 = adjusted for sex, family history of diabetes, and baseline age, current smoking, physical activity, fasting glucose, and hypertension. Model 2 = model 1 + change in fasting insulinemia. Model 3 = model 1 + change in HOMA2-IR.

*SDs for the standardization of the odds ratios in all IFG participants, BMI <25 kg/m2group, and BMI ≥25 kg/m2 group were, respectively, 0.78, 0.74, and 0.82 cm/year for change in waist circumference and 0.71, 0.62, and 0.77 kg/year for change in weight.

Odds ratios (95% CI) for 9-year incident diabetes, per 1 SD change in waist circumference and weight in IFG: the DESIR study Model 1 = adjusted for sex, family history of diabetes, and baseline age, current smoking, physical activity, fasting glucose, and hypertension. Model 2 = model 1 + change in fasting insulinemia. Model 3 = model 1 + change in HOMA2-IR. *SDs for the standardization of the odds ratios in all IFG participants, BMI <25 kg/m2group, and BMI ≥25 kg/m2 group were, respectively, 0.78, 0.74, and 0.82 cm/year for change in waist circumference and 0.71, 0.62, and 0.77 kg/year for change in weight. An increase in waist circumference remained significantly associated with progression to type 2 diabetes after controlling for concurrent changes in either insulinemia or the HOMA2-IR index, irrespective of baseline BMI category (Table 1). In contrast, the effect of weight change was no longer significant after controlling for variations in either insulinemia or the HOMA2-IR index in those with BMI <25 kg/m2.

CONCLUSIONS

The main finding of this study is that an increase in waist circumference is a major risk factor for type 2 diabetes in individuals with IFG, irrespective of baseline BMI. In those with BMI <25 kg/m2, an increase in waist circumference appears to be a stronger risk marker for progression to type 2 diabetes than weight gain. This is in agreement with a previous report that found greater risk for diabetes in U.S. men who increased their waist circumference (7); however, these authors did not specifically assess risk in IFG (7). To our knowledge, this study is the first to assess the impact of waist increase for progression to diabetes in the absence of excessive weight at baseline. Previous studies assessing risk factors for diabetes in either the general population or in IFG subjects did not perform analyses according to BMI strata (4,5). Our findings suggest the potential value of monitoring waist circumference over time in IFG. Waist circumference probably reflects more accurately visceral fat in leaner subjects because of the thinner subcutaneous abdominal depot (8). Another explanation may be that individuals with IFG and prone to develop overt diabetes tend to gain visceral fat more selectively than subcutaneous fat, compared with those who remained nondiabetic. This could be sustained by defects in adipogenesis and/or specificities in adipose tissue morphology, independently of body fat level, as recently suggested (9). However, this hypothesis cannot be demonstrated in the present study. The effect of an increase in waist circumference on the progression to diabetes was independent, at least partly, of concomitant variations in insulinemia or the HOMA2-IR index, suggesting additional mechanisms linking abdominal adiposity and β-cell function (10). Impaired β-cell function is considered an important characteristic in individuals with IFG (11), and reduced insulin secretion has been shown to be a prominent mechanism leading to diabetes in lean individuals (12,13). We speculate that an increase in waist circumference may induce further alterations in insulin secretion beyond that inherent in worsening insulin resistance. Potential mechanisms may involve β-cell lipotoxicity through enhanced free fatty acid release from adipose tissue (14). Limitations of the present study include the absence of gold-standard measures of insulin sensitivity such as the euglycemic–hyperinsulinemic clamp; strengths are the large cohort with a low prevalence of obesity and a long follow-up. In conclusion, our results emphasize the importance of monitoring and preventing increases in waist circumference in individuals with IFG, in particular in those with BMI <25 kg/m2.
  14 in total

1.  Lipid-induced beta-cell dysfunction in vivo in models of progressive beta-cell failure.

Authors:  Tracy T Goh; Timothy M Mason; Neehar Gupta; Abby So; Tony K T Lam; Loretta Lam; Gary F Lewis; Andrea Mari; Adria Giacca
Journal:  Am J Physiol Endocrinol Metab       Date:  2006-09-26       Impact factor: 4.310

2.  The natural course of beta-cell function in nondiabetic and diabetic individuals: the Insulin Resistance Atherosclerosis Study.

Authors:  Andreas Festa; Ken Williams; Ralph D'Agostino; Lynne E Wagenknecht; Steven M Haffner
Journal:  Diabetes       Date:  2006-04       Impact factor: 9.461

3.  K-value and low insulin secretion in a non-obese white population: predicted glucose tolerance after 25 years.

Authors:  M Alvarsson; A Wajngot; E Cerasi; S Efendic
Journal:  Diabetologia       Date:  2005-09-14       Impact factor: 10.122

4.  The influence of body fat distribution on the incidence of diabetes mellitus. 13.5 years of follow-up of the participants in the study of men born in 1913.

Authors:  L O Ohlson; B Larsson; K Svärdsudd; L Welin; H Eriksson; L Wilhelmsen; P Björntorp; G Tibblin
Journal:  Diabetes       Date:  1985-10       Impact factor: 9.461

5.  Glucose indices, health behaviors, and incidence of diabetes in Australia: the Australian Diabetes, Obesity and Lifestyle Study.

Authors:  Dianna J Magliano; Elizabeth L M Barr; Paul Z Zimmet; Adrian J Cameron; David W Dunstan; Stephen Colagiuri; Damien Jolley; Neville Owen; Patrick Phillips; Robyn J Tapp; Tim A Welborn; Jonathan E Shaw
Journal:  Diabetes Care       Date:  2007-11-05       Impact factor: 19.112

6.  The endocrine profile of subcutaneous and visceral adipose tissue of obese patients.

Authors:  M Dolinková; I Dostálová; Z Lacinová; D Michalský; D Haluzíková; M Mráz; M Kasalický; M Haluzík
Journal:  Mol Cell Endocrinol       Date:  2008-05-09       Impact factor: 4.102

7.  Changes in body weight and body fat distribution as risk factors for clinical diabetes in US men.

Authors:  Pauline Koh-Banerjee; Youfa Wang; Frank B Hu; Donna Spiegelman; Walter C Willett; Eric B Rimm
Journal:  Am J Epidemiol       Date:  2004-06-15       Impact factor: 4.897

8.  The metabolic syndrome as predictor of type 2 diabetes: the San Antonio heart study.

Authors:  Carlos Lorenzo; Mayor Okoloise; Ken Williams; Michael P Stern; Steven M Haffner
Journal:  Diabetes Care       Date:  2003-11       Impact factor: 19.112

Review 9.  Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies.

Authors:  Hertzel C Gerstein; Pasqualina Santaguida; Parminder Raina; Katherine M Morrison; Cynthia Balion; Dereck Hunt; Hossein Yazdi; Lynda Booker
Journal:  Diabetes Res Clin Pract       Date:  2007-06-29       Impact factor: 5.602

10.  Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR).

Authors:  Beverley Balkau; Céline Lange; Leopold Fezeu; Jean Tichet; Blandine de Lauzon-Guillain; Sebastien Czernichow; Frederic Fumeron; Philippe Froguel; Martine Vaxillaire; Stephane Cauchi; Pierre Ducimetière; Eveline Eschwège
Journal:  Diabetes Care       Date:  2008-08-08       Impact factor: 17.152

View more
  20 in total

1.  Weight change over eight years in relation to alcohol consumption in a cohort of continuing smokers and quitters.

Authors:  Deborah Lycett; Marcus Munafò; Elaine Johnstone; Michael Murphy; Paul Aveyard
Journal:  Nicotine Tob Res       Date:  2011-05-26       Impact factor: 4.244

2.  Diet soda intake is associated with long-term increases in waist circumference in a biethnic cohort of older adults: the San Antonio Longitudinal Study of Aging.

Authors:  Sharon P G Fowler; Ken Williams; Helen P Hazuda
Journal:  J Am Geriatr Soc       Date:  2015-03-17       Impact factor: 5.562

3.  Changes in Weight and Glucose Can Protect Against Progression in Early Diabetes Independent of Improvements in β-Cell Function.

Authors:  Y R Patel; M S Kirkman; R V Considine; T S Hannon; K J Mather
Journal:  J Clin Endocrinol Metab       Date:  2016-08-17       Impact factor: 5.958

4.  Role of obesity, metabolic variables, and diabetes in HIV-associated neurocognitive disorder.

Authors:  J A McCutchan; J A Marquie-Beck; C A Fitzsimons; S L Letendre; R J Ellis; R K Heaton; T Wolfson; D Rosario; T J Alexander; C Marra; B M Ances; I Grant
Journal:  Neurology       Date:  2012-02-14       Impact factor: 9.910

5.  Prediction model for the onset risk of impaired fasting glucose: a 10-year longitudinal retrospective cohort health check-up study.

Authors:  Yuqi Wang; Liangxu Wang; Yanli Su; Li Zhong; Bin Peng
Journal:  BMC Endocr Disord       Date:  2021-10-22       Impact factor: 2.763

6.  Adipokine pattern in subjects with impaired fasting glucose and impaired glucose tolerance in comparison to normal glucose tolerance and diabetes.

Authors:  Anke Tönjes; Mathias Fasshauer; Jürgen Kratzsch; Michael Stumvoll; Matthias Blüher
Journal:  PLoS One       Date:  2010-11-09       Impact factor: 3.240

7.  Validation of a nomogram for predicting regression from impaired fasting glucose to normoglycaemia to facilitate clinical decision making.

Authors:  Vivian Yw Guo; Esther Yt Yu; Carlos Kh Wong; Regina Ws Sit; Jenny Hl Wang; S Y Ho; Cindy Lk Lam
Journal:  Fam Pract       Date:  2016-05-03       Impact factor: 2.267

8.  Association of -2518A>G promoter polymorphism in the monocyte chemoattractant protein-1 (MCP-1) gene with type 2 diabetes and coronary artery disease.

Authors:  Ramandeep Kaur; Kawaljit Matharoo; Punit Arora; A J S Bhanwer
Journal:  Genet Test Mol Biomarkers       Date:  2013-08-09

9.  Androidal fat dominates in predicting cardiometabolic risk in postmenopausal women.

Authors:  O A Matvienko; D L Alekel; S N Bhupathiraju; H Hofmann; L M Ritland; M B Reddy; M D Van Loan; C D Perry
Journal:  Cardiol Res Pract       Date:  2010-12-19       Impact factor: 1.866

10.  Body mass index and waist circumference according to glucose tolerance status in Korea: the 2005 Korean Health and Nutrition Examination Survey.

Authors:  Hye Mi Kang; Dong-Jun Kim
Journal:  J Korean Med Sci       Date:  2012-04-25       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.